Skip to the page

Data / Form D filings / Deverra Therapeutics, Inc.

Deverra Therapeutics, Inc.: Form D filings

Deverra Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 2 Form D notices with the SEC between 2020 and 2023. The latest, on September 18, 2023, reports $2.4 million sold of a $2.4 million offering to 1 investor.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1600 FAIRVIEW AVENUE EAST, SUITE 300, Seattle, WA, 98102
Phone
(214) 478-8208
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2019
Revenue range
No Revenues
Exemptions claimed
Rule 506(b), Investment Company Act section 3(c), section 3(c)(1)
SEC identifier (CIK)
1822782

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Sep 18, 2023New notice$2,388,889$2,388,8891Sep 8, 2023sec.gov
Aug 27, 2020New notice$3,500,000$75,000$3,425,0002Aug 20, 2020sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Michael YurkowskyExecutive Officer
Colleen DelaneyExecutive Officer

Other biotechnology companies in Washington that filed recently

Every Form D from the week of Sep 18, 2023 · All recent filings in Washington · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Deverra Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.